DEYZOLY
Live / Allowed — Publication / registration review complete (as of 07 Oct 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 27 Nov 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 79446709
- Mark type
- Word mark
- Filed
- 27 Nov 2025
- Published for opposition
- 27 Oct 2026
- Attorney of record
- Miriam D. Trudell
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia; medical preparations for the treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia
- Class 010 — Medical apparatus: Medical devices for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders, namely, short bowel syndrome (SBS) in humans by introducing pharmaceutical preparations, and parts and fittings therefor; medical devices for treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia by introducing pharmaceutical preparations, and parts and fittings therefor
- Class 044 — Medical, beauty and agricultural services: Medical services, namely, treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS) and pharmaceutical services, namely, treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical and pharmaceutical advice in the field of treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical services, namely, treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia and pharmaceutical services, namely, treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia
Owner
Prosecution history
- 29 Sept 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 28 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 11 Jun 2026 — REFUSAL PROCESSED BY IB
- 23 May 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 23 May 2026 — REFUSAL PROCESSED BY MPU
- 09 Apr 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 08 Apr 2026 — NON-FINAL ACTION WRITTEN
- 31 Mar 2026 — ASSIGNED TO EXAMINER
- 27 Mar 2026 — APPLICATION FILING RECEIPT MAILED
- 27 Mar 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 26 Mar 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB